The estimated Net Worth of Denis M Odonnell is at least $3.97 Milhão dollars as of 9 March 2006. Denis Odonnell owns over 231,555 units of Novavax stock worth over $2,722,174 and over the last 21 years Denis sold NVAX stock worth over $1,248,081.
Denis has made over 1 trades of the Novavax stock since 2006, according to the Form 4 filled with the SEC. Most recently Denis sold 231,555 units of NVAX stock worth $1,248,081 on 9 March 2006.
The largest trade Denis's ever made was selling 231,555 units of Novavax stock on 9 March 2006 worth over $1,248,081. On average, Denis trades about 33,079 units every 0 days since 2003. As of 9 March 2006 Denis still owns at least 221,495 units of Novavax stock.
You can see the complete history of Denis Odonnell stock trades at the bottom of the page.
Denis's mailing address filed with the SEC is , , , , .
Over the last 23 years, insiders at Novavax have traded over $136,088,511 worth of Novavax stock and bought 2,908,869 units worth $5,634,467 . The most active insiders traders include David M Mott, Rajiv I. Modi, eGary C Evans. On average, Novavax executives and independent directors trade stock every 25 days with the average trade being worth of $907,678. The most recent stock trade was executed by John Trizzino on 19 August 2024, trading 655 units of NVAX stock currently worth $8,050.
novavax, inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. our recombinant nanoparticles and matrix-m™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. product pipeline our product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus ("rsv"), seasonal influenza, pandemic influenza, and ebola virus ("ebov"). we have additional preclinical-stage programs for a variety of infectious diseases. corporate overview novavax is headquartered in gaithersburg, maryland with additional facilities in rockville, maryland and uppsala, sweden. novavax is traded on the nasdaq stock market under the symbol nvax and employs over 300 individuals dedicated to developing novel vaccines to address infectious disease.
Novavax executives and other stock owners filed with the SEC include: